Nature Medicine, Published online: 21 July 2025; doi:10.1038/s41591-025-03894-2Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the
Nature Medicine, Published online: 21 July 2025; doi:10.1038/s41591-025-03894-2Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the
Nature Medicine, Published online: 21 July 2025; doi:10.1038/s41591-025-03894-2Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the
Nature Medicine, Published online: 21 July 2025; doi:10.1038/s41591-025-03894-2Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the
Nature Medicine, Published online: 21 July 2025; doi:10.1038/s41591-025-03894-2Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the
Nature Medicine, Published online: 21 July 2025; doi:10.1038/s41591-025-03895-1Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2
Nature Medicine, Published online: 21 July 2025; doi:10.1038/s41591-025-03895-1Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2
Nature Medicine, Published online: 21 July 2025; doi:10.1038/s41591-025-03895-1Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2